Copyright
©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 28, 2014; 20(8): 1972-1985
Published online Feb 28, 2014. doi: 10.3748/wjg.v20.i8.1972
Published online Feb 28, 2014. doi: 10.3748/wjg.v20.i8.1972
Study | Study design | Patients | Baseline Hb (g/dL) | Iron compound dose (mg) | Duration (wk) | Hb (g/dL) | ABT (% or U/pt) |
Oral iron | |||||||
Okuyama et al[46] | OBS | Iron: 32 | 8.1 ± 1.4 | Ferrous citrate | ≥ 2 | 2.0 | 9.4% |
No iron: 84 | 8.0 ± 1.6 | (200 mg/d) | 0.9 | 27.4% | |||
Lidder et al[47] | RCT | Iron: 23 | 13.4 ± 1.9 | FS | 2-8 | -0.3 | 26.0% |
No iron: 22 | 12.4 ± 2.1 | (200 mg TDS) | -0.6 | 59.0% | |||
Quinn et al[48] | OBS | Iron: 103 | 12 (10-14) | FS | 1-9 | 0.69 U/pt | |
No iron: 167 | NS | (200 mg TDS) | 1.69 U/pt | ||||
Ferrari et al[49] | RCT | FB: 12 | 11.6 ± 1.6 | FB | 8 | 1 (2) mo | NS |
(28-14 mg/d) | 0.8 (1.4) | ||||||
FS: 12 | 11.3 ± 1.2 | FS | 0.7 (1.4) | ||||
(105 mg/d) | |||||||
Intravenous iron | |||||||
Edwards et al[57] | RCT | Iron: 34 | 13.7 ± 0.5 | IS | 2 | -0.2 | 14.7% |
Placebo: 26 | 13.4 ± 0.4 | (2 × 300 mg) | -0.5 | 19.2% | |||
Bisbe et al[64] | OBS | IS: 30 | 10.1 ± 1.2 | IS | 2-6 | 0.9 | 7.0% |
(100-200 mg, 6 ± 3 doses) | |||||||
FCM: 15 | 9.2 ± 1.0 | FCM | 2.5 | 40.0% | |||
(500-1000 mg, 3 ± 1 doses) | |||||||
Todman et al[68] | Case series | Iron: 22 | < 12 | Iron isomaltoside-1000 | 2-6 | 0.7, 1-2 w | NS |
(20 mg/kg bw) | 1.4, 3-4 w | ||||||
3.1, 6-8 w |
- Citation: Muñoz M, Gómez-Ramírez S, Martín-Montañez E, Auerbach M. Perioperative anemia management in colorectal cancer patients: A pragmatic approach. World J Gastroenterol 2014; 20(8): 1972-1985
- URL: https://www.wjgnet.com/1007-9327/full/v20/i8/1972.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i8.1972